Eva Conde Garcia, PhDEva received her BS at University of Barcelona (Spain) and then move to Paris (France) to do her MS at University Pierre and Marie Curie. She did her PhD in Sorbonne University, in Paris, working at Pasteur Institute. She did an industrial PhD working in collaboration with a French Biotech, Neovacs SA, to develop new vaccines strategies to treat allergic disorders. Under the supervision of Dr. Laurent Reber, they developed two therapeutic vaccines targeting self proteins playing major roles in allergic disorders: IL-4, IL-13 and IgE.
Eva joined Khanna lab in 2021 to carry out studies centered upon understanding the host immune response to viral infections such as influenza and SARS-CoV2. She is interested to understand how macrophages subsets respond to viral infections in vivo during respiratory infections. She will be using conditional gene knock out preclinical mouse models to determine if specific population of innate immune cells can be targeted for therapy against morbidity associated with the respiratory infections. Fun fact: Eva loves staying active and do sports! She is keen any time for hiking, dance classes, yoga, and will volunteer for discovering new activities. She will always be ready for a nice glass of wine or a cup of tea with friends and colleagues. Her favorite place to be is by the sea. Home town: Barcelona, Spain Currently a postdoctoral researcher at Regeneron |
Publications |
Dual vaccination against IL-4 and IL-13 protects against chronic allergic asthma in mice.
E Conde, R Bertrand, B Balbino, J Bonnefoy, J Stackowicz, N Caillot, F Colaone, S Hamdi, R Houmadi, A Loste, J Kamphuis, F Huetz, L Guilleminault, N Gaudenzio, A Mougel, D Hardy, J Snouwaert, B Koller, VSerra, P Bruhns, G Grouard-Vogel, LL Reber. Accepted in Nature Communications. Comment on "Tumor-initiating cells establish an IL-33-TGF-β niche signaling loop to promote cancer progression". Kamphuis JBJ, Worrall WPM, Stackowicz J, Mougel A, Mauré E, Conde E, Bruhns P, Guilleminault L, Gaudenzio N, Chen J, Gentek R, Reber LL.Science. 2021 Apr 9;372(6538):eabf2022. doi: 10.1126/science.abf2022.PMID: 33833094 Approaches to target IgE antibodies in allergic diseases. Balbino B, Conde E, Marichal T, Starkl P, Reber LL.Pharmacol Ther. 2018 Nov;191:50-64. doi: 10.1016/j.pharmthera.2018.05.015. Epub 2018 Jun 27.PMID: 29909239 Review. |